步长制药中药出海等战略有序推进 创新药管线加速兑现

Core Viewpoint - Shandong Buchang Pharmaceutical's subsidiary, Luzhou Buchang, has signed an exclusive supply agreement with Malaysian company MEDISPEC, marking a significant step in the company's "Traditional Chinese Medicine Internationalization" strategy [1] Group 1: Internationalization Strategy - The signing of the agreement reflects the deepening of Buchang Pharmaceutical's internationalization strategy, with recent product registrations in Malaysia, Mongolia, and Indonesia [2] - The company's sales network now covers dozens of countries, including the US, Canada, and Vietnam, and is actively expanding into Latin America [2] - Buchang Pharmaceutical aims to make "Chinese prescriptions" an international medical option and promote traditional Chinese culture [2] Group 2: R&D and Product Development - Buchang Pharmaceutical is advancing in innovative drug development, with significant progress in its pipeline across biological, traditional Chinese, and chemical drugs [4] - The company has received approvals for 17 generic drugs in 2023, with over 170 products included in the 2025 National Medical Insurance Directory, including 73 exclusive products [4] - Exclusive products have generated over 10.3 billion yuan in sales in the first three quarters of 2025, providing strong support for ongoing innovation [4] Group 3: Shareholder Returns - The company has returned 7.948 billion yuan to shareholders through regular high dividends and share buybacks, exceeding the total IPO fundraising amount [5] - In 2025 alone, the company repurchased 6.6206 million shares, spending nearly 100 million yuan, and completed the cancellation of 51.47 million shares [5] Group 4: Social Responsibility - Buchang Pharmaceutical has sponsored the "Together, Build China's Heart" public welfare project for 18 consecutive years, providing medical assistance to over a million people [6] - The company emphasizes the dual focus on innovation and social responsibility, aiming to create greater social value while advancing pharmaceutical innovation [6]